ARMP — Armata Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $214.80m
- $346.36m
- $5.17m
- 14
- 10
- 81
- 26
Annual cashflow statement for Armata Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.2 | -23.2 | -36.9 | -69 | -18.9 |
| Depreciation | |||||
| Non-Cash Items | 3.67 | 1.63 | 3.1 | 30.3 | -17.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.874 | -3.22 | 0.439 | -9.65 | -2.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -18.3 | -23.6 | -32.5 | -47.4 | -37.6 |
| Capital Expenditures | -0.824 | -1.3 | -2.21 | -8.14 | -1.88 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | 0.01 | 0 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.824 | -1.3 | -2.21 | -8.13 | -1.88 |
| Financing Cash Flow Items | -0.568 | -1.41 | -0.5 | -0.043 | -0.061 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23.2 | 25.5 | 44 | 54 | 35 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.12 | 0.639 | 9.32 | -1.57 | -4.47 |